home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490751.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
3KB
|
50 lines
Document 0751
DOCN M9490751
TI Carnitine depletion in peripheral blood mononuclear cells from patients
with AIDS: effect of oral L-carnitine.
DT 9411
AU De Simone C; Famularo G; Tzantzoglou S; Trinchieri V; Moretti S; Sorice
F; Department of Infectious Diseases, University of L'Aquila, Italy.
SO AIDS. 1994 May;8(5):655-60. Unique Identifier : AIDSLINE MED/94338602
AB OBJECTIVE: Reduced levels of serum carnitines
(3-hydroxy-4-N-trimethyl-ammonio-butanoate) are found in most patients
treated with zidovudine. However, since serum carnitines do not strictly
reflect cellular concentrations we examined whether a carnitine
depletion could be found in peripheral blood mononuclear cells (PBMC)
from AIDS patients with normal serum carnitine levels. In addition, we
explored whether it was possible to relate the host's immunoreactivity
to the content of carnitine in PBMC and whether carnitine levels can be
corrected by oral supplementation of L-carnitine. DESIGN:
Immunopharmacologic study. METHODS: Twenty male patients with advanced
AIDS (Centers for Disease Control and Prevention stage IVCI) and normal
serum levels of carnitines were enrolled. Patients were randomly
assigned to receive either L-carnitine (6 g/day) or placebo for 2 weeks.
At baseline and at the end of the trial, we measured carnitines in both
sera and PBMC, serum triglycerides, CD4 cell counts, and the frequency
of cells entering the S and G2-M phases of cell cycle following mitogen
stimulation. RESULTS: Concentrations of total carnitine in PBMC from
AIDS patients was lower than in healthy controls. A significant trend
towards the restoration of appropriate intracellular carnitine levels
was found in patients treated with high-dose L-carnitine and was
associated with an increased frequency of S and G2-M cells following
mitogen stimulation. Furthermore, at the end of the trial we found a
strong reduction in serum triglycerides in the L-carnitine group
compared with baseline levels. CONCLUSIONS: Our data indicate that
carnitine deficiency occurs in PBMC from patients with advanced AIDS,
despite normal serum concentrations. The increase in cellular carnitine
content strongly improved lymphocyte proliferative responsiveness to
mitogens. Because carnitine status is an important contributing factor
to immune function in patients with advanced AIDS, we therefore believe
that L-carnitine supplementation could have a role as a complementary
therapy for HIV-infected individuals.
DE Acquired Immunodeficiency Syndrome/*BLOOD Administration, Oral Adult
Carnitine/ADMINISTRATION & DOSAGE/BLOOD/*DEFICIENCY/*THERAPEUTIC USE
Cell Cycle Human Intracellular Fluid/CHEMISTRY Leukocyte Count
Leukocytes, Mononuclear/*CHEMISTRY Lymphocyte Transformation Male
Triglycerides/BLOOD T4 Lymphocytes CLINICAL TRIAL JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).